Reprogramming Glioblastoma Cells into Non-Cancerous Neuronal Cells as a Novel Anti-Cancer Strategy

Area of Science:

• Neuroscience
• Oncology
• Cell Biology

Background:

• Glioblastoma Multiforme (GBM) is a highly aggressive brain tumor with poor prognosis.
• Direct cell lineage reprogramming offers a potential therapeutic strategy for neurological diseases.
• NeuroD1 (ND1) is a key transcription factor known to induce neuronal differentiation.

Purpose of the Study:

• To investigate if NeuroD1 (ND1) expression can induce glioblastoma (GBM) cells to differentiate into post-mitotic neurons.
• To assess the impact of ND1-induced neuronal transdifferentiation on GBM cell proliferation, survival, and migration.
• To evaluate the therapeutic potential of ND1-mediated reprogramming in preclinical GBM models.

Main Methods:

• Adeno-associated virus (AAV)-mediated delivery of NeuroD1 (ND1) to human GBM cell lines (LN229, U87, U373, T98G).
• Assessment of neuronal marker expression (MAP2, TUJ1, NeuN) and proliferation (BrdU), cell death (TUNEL), and migration (wound-healing assay).
• In vivo studies involving orthotopic transplantation of ND1-reprogrammed GBM cells into a mouse model.

Main Results:

• ND1 expression successfully induced neuronal lineage conversion in various GBM cell lines, including temozolomide-resistant T98G cells.
• Reprogrammed GBM cells exhibited reduced proliferation, increased cell death, and decreased migratory capacity.
• ND1-reprogrammed GBM cells expressed neuronal markers and the anti-tumorigenic gene p53.
• In vivo studies showed smaller tumor formation and neuronal marker expression in ND1-treated GBM models.

Conclusions:

• Single-factor NeuroD1 (ND1) reprogramming effectively converts malignant GBM cells into neuron-like cells, overcoming drug resistance.
• This reprogramming strategy halts GBM tumor progression by reducing proliferation and migration, and inducing cell death.
• ND1-mediated cellular reprogramming represents a promising therapeutic avenue for glioblastoma and potentially other astrocytoma tumors.